Clearwater Analytics (CWAN) Q1 2026 earnings review
A Strong Final Act Before the Private Equity Exit
Clearwater Analytics capped off its first full year of integrating three major acquisitions (Enfusion, Beacon, Bistro) with a pristine Q1 report. Revenue surged 74% YoY to $221.2 million, and Annualized Recurring Revenue (ARR) hit $872 million. Most impressively, Adjusted EBITDA margin rebounded to 35.0%, fully reversing the margin dilution caused by the acquisitions last spring. This proves management's playbook worked. However, forward-looking analysis is largely moot: shareholders have approved an $8.4 billion buyout by Permira and Warburg Pincus ($24.55/share). With only Australian regulatory approval pending, the company has suspended all forward guidance and earnings calls.
🐂 Bull Case
The margin recovery is complete. Adjusted EBITDA margin has climbed back to 35.0%, matching pre-acquisition levels. Management successfully absorbed lower-margin businesses without destroying the core profitability engine.
With $872M in ARR and a comprehensive front-to-back platform, CWAN has cemented itself as an indispensable utility for the investment management industry. Total assets supported now exceed $10 trillion globally.
🐻 Bear Case
Net Revenue Retention (NRR) has settled at 108%, a noticeable step down from the 114% enjoyed a year ago. Gross Revenue Retention also ticked down to 97%.
While highly likely to close, the transaction still requires approval from the Australia Foreign Investment Review Board (FIRB), leaving a sliver of regulatory tail risk.
⚖️ Verdict: ⚪
Neutral. Operationally, the company is performing exceptionally well, having digested massive acquisitions while expanding margins. However, the pending $8.4 billion all-cash acquisition anchors the stock price, removing future upside potential for public market investors.
Key Themes
Margin Synergy Playbook Executed
When Clearwater bought Enfusion and Beacon in Q2 2025, operating margins initially took a hit. Management promised aggressive cost synergies and operational overhauls. One year later, the results are undeniable. Non-GAAP Gross Profit grew 73% to $172.7M (78.1% margin), and Adjusted EBITDA grew 72% to $77.4M. The margin drag from the acquisitions has been entirely neutralized.
Retention Metrics Have Cooled
While headline growth is stellar, underlying retention efficiency is decelerating. Net Revenue Retention (NRR) printed at 108%, stable sequentially but down significantly from the 114% reported in Q1 2025 prior to the acquisitions. Furthermore, Gross Revenue Retention slipped to 97% from its historical 98-99% range. The combined client base is proving slightly less sticky or harder to upsell than the legacy Clearwater base.
GenAI Transitioning From Buzzword to Margin Driver
Management explicitly credited GenAI tools for enabling the 73% surge in Non-GAAP Gross Profit. By weaving these tools into internal operations, CWAN has allowed both technical and non-technical employees to automate manual reconciliation and reporting. This operational leverage is the structural reason the company was able to absorb Enfusion's lower-margin profile so quickly.
Front-to-Back Cross-Sell Gaining Traction
The strategic rationale for the Enfusion and Beacon acquisitions was to create a unified front-to-back platform. Q1 provided solid proof points: Orange Investment Advisors and Dunamis Asset Management both adopted Enfusion by Clearwater for unified PMS, OMS, and execution. The ability to bundle front-office trading with back-office accounting is actively replacing siloed legacy systems.
Other KPIs
The company remains slightly unprofitable on a GAAP basis, driven by $28.6M in equity-based compensation and $29.6M in depreciation and amortization—heavy burdens stemming directly from last year's M&A activity. However, the loss has narrowed significantly from the $(24.2)M nadir in Q2 2025.
Decelerating. FCF was relatively weak compared to the $77.4M in Adjusted EBITDA and down from $23.0M a year ago. This disconnect was largely driven by a $32.8M cash outflow related to accrued expenses and other liabilities, a typical working capital fluctuation post-acquisition.
Guidance
Stable. Due to the pending $8.4 billion acquisition by the Permira and Warburg Pincus-led investor group, management has officially suspended all forward-looking financial guidance. The transaction is expected to close in Q2 2026.
Key Questions
NRR Recovery Path
Net Revenue Retention has compressed to 108% post-acquisitions. With the Enfusion commercial model changes theoretically taking effect in 2026, when do you expect NRR to inflect back toward the historical 114-115% target?
Cash Flow Dynamics
Operating cash flow and Free Cash Flow were relatively suppressed this quarter despite record Adjusted EBITDA. Can you detail the specific working capital timing issues or liability payouts that constrained cash generation in Q1?
International Expansion Strategy
The onboarding of Dunamis Asset Management highlights growth in Korea and Hong Kong. How is the Asian expansion strategy prioritizing the deployment of Enfusion front-office solutions versus legacy Clearwater accounting?